Document:

<PAGE>   1

                                                                   EXHIBIT 10.27

                                                                ----------------
                                                                REDACTED VERSION
                                                                ----------------

                    CLINICAL MANUFACTURE AND SUPPLY AGREEMENT

      THIS AGREEMENT (the "Agreement") is entered into on January 25, 2001 by
and between ABC Laboratories, Inc., of Columbia, Missouri ("ABC") and NeoRx
Corporation, of Seattle, Washington ("NeoRx"). The Agreement becomes effective
on January 15, 2001 and supercedes the Clinical Manufacture and Supply Agreement
between ABC and NeoRx dated September 1, 2000.

                                   WITNESSETH

      WHEREAS, ABC desires to manufacture (166)Ho-DOTMP at the
radiopharmaceutical manufacturing facility located in rooms 111, 222, 232 and
232B at Missouri University Research Reactor ("MURR") in Columbia, Missouri (the
"Facility"); and

      WHEREAS, NeoRx desires that ABC manufacture and supply to and on behalf of
NeoRx, and ABC is willing to manufacture and supply, certain quantities of [*]
((166)Ho-DOTMP) (the "Product") for NeoRx's use in clinical trials, all in
accordance with the terms and conditions set forth in this Agreement;

      [*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT
      TO A REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE
      COMMISSION.

      NOW THEREFORE, in consideration of the foregoing promises and agreements
set forth herein, the parties agree as follows:

                                    AGREEMENT

I.    SCOPE OF WORK

      (A)   Processing Responsibilities. ABC will (1) manufacture, analyze,
package in dosage form, and inspect and label (collectively "Process") Product
at the Facility in accordance with cGMP and the Product specifications set forth
on Exhibit A (which is incorporated herein by this reference), unless NeoRx
Quality Assurance approves (on a per batch basis) in writing any deviation in
batch test result(s) from Product specifications; (2) maintain records regarding
the Product in conformity with cGMP; and (3) supply the Product to NeoRx in such
doses as NeoRx may order from ABC in accordance with this Agreement. NeoRx
acknowledges that ABC can Process Product only as permitted by MURR Health
Physics ("HP"). Furthermore, NeoRx acknowledges that in order to perform the
process, ABC must [*].

      (B)   QA/QC Release Testing. ABC will perform all QA/QC release testing on
each batch of Product as required pursuant to cGMP and the Product
specifications set forth on Exhibit A.

                                      -1-
<PAGE>   2

      (C)   Procurement Responsibilities. ABC will procure, test, release, and
maintain sufficient inventory of raw materials, manufacturing and QC components
and reagents necessary to Process the Product in accordance with this Agreement,
other than (1) DOTMP supplied by NeoRx and (2) (166)HoCl(3) supplied by MURR. If
ABC is unable to procure certain raw materials, it may request NeoRx to provide
assistance with the procurement of certain other raw materials.

      (D)   Record Keeping and Access. ABC will make available to NeoRx and any
applicable governmental agency all records relating to the Process and Facility
as they relate to the Product.

      (E)   Facility Access and Inspection. ABC will permit NeoRx and FDA
inspectors to access and inspect the Facility (as permitted by MURR HP) to
ensure that the Product is being Processed in accordance with cGMP and the
Product specifications as set forth on Exhibit A.

      (F)   Certificate of Analysis. ABC will provide to NeoRx a certificate of
analysis in a form agreed to by the parties and in compliance with all
applicable laws, for each batch of Product, provided a certificate of analysis
for (166)HoCl(3) is provided to ABC by MURR prior to completion of the Process.

      (G)   Waste Disposal. ABC shall be responsible for the treatment and/or
disposal of all waste generated at ABC during the manufacturing process in
accordance with established federal, state and local environmental and OSHA laws
and regulations, and the maintenance of detailed and complete records related
thereto.

      II.   PURCHASE ORDERS

      (A)   Purchase Orders. NeoRx will deliver to ABC by the close of business
on Monday of each week during the term of this Agreement, a written or
electronic purchase order for batch Processing (and whether each batch is a [*]
that NeoRx desires to purchase during the following calendar week. Each purchase
order will also specify the delivery dates and the number of doses of Product
that are to be shipped to each location. Each dose shall be shipped in such
manner, and to such location, as directed by NeoRx and as permitted by MURR HP.

      (B)   Contradictory Provisions. To the extent any purchase order, or
related invoice, contains any provisions contrary to the terms of this
Agreement, such contrary provisions shall have no force or effect and the terms
of this Agreement shall control.

      III.  FEES

      (A)   Project Initiation Fees. NeoRx agrees to pay ABC [*] as full
compensation for services rendered and expenses incurred on behalf of NeoRx but
beyond the scope of the Clinical Manufacture and Supply Agreement dated
September 1, 2000. These fees are to be paid in [*] (the "Monthly Project
Initiation Fees").

      (B)   Full-Time Equivalent Fees. For the duration of the Agreement, NeoRx
agrees to pay ABC [*] per month (the "Full-Time Equivalent Fees") for providing
[*] to NeoRx in support of this Agreement and other projects as designated by
NeoRx and agreed to by ABC. In the

                                      -2-
<PAGE>   3

event of any necessary change [*], ABC shall immediately notify NeoRx, and the
parties shall work together in good faith [*].

      (C)   Process Fees. NeoRx and ABC acknowledge the developmental nature of
the Process and that unanticipated procedures or additional Process revisions
may be required. Accordingly, Process fees include a fixed per batch component
for the Process, in accordance with normal protocol and batch record
requirements as of the date of the Agreement, and a time and material component
for variable costs and additional Process revisions.

            (1)   Fixed Process Fees. For each batch Processed during the term
      of this Agreement, NeoRx shall pay ABC a fee of [*]. The price per batch
      includes the cost of [*] to manufacture the product.

            (2)   Time and Material Process Fees. NeoRx shall reimburse ABC for
      [*]. The fees described in this Section III(C)(2) are collectively
      referred to as the "Process Time and Material Fees."

      (D)   QA/QC Fees. Consistent with Process fees, the QA/QC fees include a
fixed per batch component for normal Process QA/QC testing, in accordance with
normal protocol and batch record requirements as of the date of this Agreement,
and a time and material component for variable costs and additional QA/QC
testing revisions.

            (1)   Fixed QA/QC Fees. For each batch Processed during the term of
      this Agreement, NeoRx shall pay ABC a fee of [*]. The price per batch
      includes [*].

            (2)   Time and Material QA/QC Fees. NeoRx shall reimburse ABC for
      [*]; provided, however the parties agree that ABC shall incur no costs
      under this Section III(C)(2) without NeoRx's prior written approval. The
      fees described in this Section III(C)(2) are collectively referred to as
      the "QA/QC Time and Material Fees."

      (E)   Minimum Purchase Requirement. During the period from the effective
date of the Agreement until December 31, 2002, NeoRx agrees to pay, at a
minimum, [*].

IV.   BILLING AND PAYMENT TERMS

      ABC shall invoice NeoRx periodically, but at least monthly, for fees
earned and defined in Section III. NeoRx shall pay such invoices within thirty
(30) days of its receipt. All invoices that remain unpaid after sixty (60) days
of NeoRx's receipt thereof shall accrue interest at the rate of 1.5% per month.
ABC shall reference the applicable purchase orders on all invoices. If NeoRx
disagrees for any reason with an amount of an invoice, NeoRx shall notify ABC in
writing of such a disagreement within ten (10) business days of receipt of such
invoice, and the parties shall promptly endeavor to resolve the dispute in good
faith.

V.    SHIPPING TERMS

      NeoRx will be responsible for the shipment of the Product and liable for
any losses resulting from such shipment. NeoRx, in consultation with ABC, shall
arrange for the shipment

                                      -3-
<PAGE>   4

of the Product from the Facility to NeoRx, or such other location(s) as
determined by NeoRx. NeoRx shall be responsible for the payment of all shipping
charges (including, without limitation, freight, handling, insurance and all
other transportation-related items associated with such shipments).

VI.   TERM AND TERMINATION

      This Agreement will continue through [*]; provided, however, that either
party may terminate this agreement after [*], upon 180 days prior written notice
(such notice cannot be given prior to [*]); and provided, however, that either
party may terminate this Agreement if the other party breaches any of its
obligations hereunder and does not cure such breach within ten (10) days of
written notice or, if such breach is of a nature which, using its best efforts,
the breaching party cannot cure within ten (10) days, if the breaching party
fails to cure such breach within thirty (30) days after the expiration of the
cure period. Notwithstanding any provision in this Agreement to the contrary,
ABC shall continue to Process the Product and deliver the Product in response to
any Purchase Order, through the date of termination, unless such Process and
delivery requirements are waived in writing by NeoRx.

      Upon termination by NeoRx (unless as a result of breach which is not cured
by ABC) or breach which is not cured by NeoRx or expiration of this Agreement,
ownership of all equipment and instrumentation used in the Process and QA/QC
testing and maintained at the Facility will be transferred from NeoRx to ABC;
provided, however, that ABC will keep the Facility intact through [*] to permit
NeoRx and FDA inspectors to access and inspect the Facility and Process to
ensure that the Product was manufactured and released in accordance with cGMP
and the Product specifications as set forth on Exhibit A; [*].

VII.    MISCELLANEOUS

      (A)   Each party may receive information from the other party that the
receiving party should reasonably believe is confidential. Each party will hold
the other party's confidential information in confidence, including the terms of
this Agreement, and will disclose such information to persons on a need to know
basis only.

      (B)   This Agreement contains the entire understanding of the parties and
supersedes all prior agreements and understandings, and may not be modified, nor
any term waived, except by the unanimous written consent of the parties.

      (C)   The parties are acting as independent contractors and independent
employers. Nothing herein shall be construed as creating a partnership, joint
employer or agency relationship between the parties and no party shall have
authority to bind the other in any respect.

      (D)   In the event any provision of this Agreement is held unenforceable
under applicable law, the remainder of the Agreement shall remain valid.

      (E)   No patent, trademark, logo, copyright or other intellectual property
rights are conveyed by this Agreement, and neither party shall have the right to
use the other parties intellectual property for any purpose whatsoever without
prior written consent.

                                      -4-
<PAGE>   5

      (F)   NeoRx assumes responsibility for payment or settlement of all
charges from [*]. NeoRx agrees to indemnify and hold ABC harmless with respect
to the resolution of any [*].

      (G)   During the Term of this Agreement, neither Party shall make any
press release or other disclosure of the terms of this Agreement without the
prior written consent of the other Party.

      (H)   ABC will be excused from performing the Process if its performance
is delayed or prevented by any cause beyond ABC's reasonable control including,
but not limited to, acts of God, fire, explosion, earthquake, disease, weather,
war, sabotage, government action, or accidents. Performance shall be excused
only to the extent of and during the reasonable continuance of such cause. If
such cause results in loss or damage to the materials used in the Process, NeoRx
will hold ABC harmless for any such loss or damage. ABC will immediately notify
client if, because of any of the causes referred herein, ABC is unable to
complete a Process. If any part of the Process is rendered invalid because of
such cause, ABC will, on written request from NeoRx, repeat the Process at the
cost of NeoRx. Performance shall also be excused if the FDA (or other
governmental agency with authority), Missouri Department of Health or other
regulatory agency orders ABC to cease Processing the Product or orders NeoRx to
permanently cease developing or utilizing the Product.

      (I)   NeoRx will be excused from performance under this Agreement if such
performance is delayed or prevented by any cause beyond NeoRx's reasonable
control including, but not limited to, acts of God, fire, explosion, earthquake,
disease, weather, war, sabotage, government action, or accidents. Performance
shall be excused only to the extent of and during the reasonable continuance of
such cause. Performance shall also be excused if the FDA (or other governmental
agency with authority), Missouri Department of Health or other regulatory agency
orders ABC to cease Processing the Product or orders NeoRx to permanently cease
developing or utilizing the Product.

      (J)   ABC will not be liable to NeoRx for any loss or expense resulting
from any claim arising out of NeoRx's sale, use or marketing of the Product. In
no event will ABC be liable for any lost profits or other indirect or
consequential loss or damage incurred by NeoRx.

      (K)   Each Party shall defend, indemnify, and hold harmless the other
Party, its officers, agents, employees and Affiliates (collectively, the
"Indemnified Party") from any third party loss, claim, action, damage, expense
or liability (including defense costs and reasonable attorneys' fees) arising
out of the Indemnifying Party's (a) breach, violation or non fulfillment of any
of its covenant, agreements, representations or warranties under this Agreement,
(b) handling, possession, or use of the Product, (c) negligence or willful
misconduct, or (d) breach of any third party's trade secret right, except to the
extent that such loss, claim, action, damage, expense or liability is based on,
arises out of, or is due to the negligence or willful misconduct of, or breach
of this Agreement by the Indemnified Party.

                                      -5-
<PAGE>   6

VIII. INSURANCE

      (A)   Product Liability Insurance. NeoRx shall obtain and maintain in
effect, with financially sound and reputable insurers, carrying no less than a
Best Rating of A V., Clinical Trial Products Liability insurance or indemnity
policies in a form acceptable to both parties which name ABC as an additional
insured, with respect to the manufacture, sale and use of commercial products
produced by NeoRx that contain Products. Such insurance policies shall be in an
amount not less than [*] per occurrence and in the aggregate.

      (B)   Manufacturer's Insurance. ABC shall obtain and maintain in effect in
a form acceptable to both parties, with financially sound and reputable insurers
carrying no less than a Best Rating of A V., insurance or indemnity policies as
described in section VIII(D) with a minimum aggregate coverage of not less than
[*] per occurrence and in the aggregate, naming NeoRx as an additional insured,
with respect to the Processing of the Products according to the Requirements.

      (C)   Evidence of Insurance. Each party shall supply to the other copies
of certificates of insurance giving evidence of procurement of the insurance in
the amounts specified in this Article VIII (including the naming of the other
party as an additional insured, where required).

      (D)   Type of Insurance. ABC will carry the following types of insurance -
Commercial, General Liability, Products Liability, and property insurance with
"all risk" coverage on a replacement cost and agreed amount basis, including
coverage for business interruption, contingent business interruption, extra
expense covering lost profits and continuing payroll and endorsed to include
coverage for the extended period of indemnity in a form acceptable to both
parties. Both parties also acknowledge that ABC is actively pursuing the
establishment of pollution/radioactive contamination liability insurance and
will have obtained such coverage on or about March 1, 2001.

      IN WITNESS WHEREOF, each party has caused this Agreement to be executed by
a duly authorized representative, effective on this date first set forth above.

NEORX CORPORATION                         ABC LABORATORIES, INC.

By:___________________________________    By:__________________________________

Name:_________________________________    Name:________________________________

Title:________________________________    Title:_______________________________

                                      -6-
<PAGE>   7

                                    EXHIBIT A
                               ITEM SPECIFICATIONS

                                       [*]

                                      -7-<PAGE>   1

                                                                   EXHIBIT 10.28

                                                                ----------------
                                                                REDACTED VERSION
                                                                ----------------

                         [LETTER HEAD OF CR STRATEGIES]

                            MASTER SERVICE AGREEMENT

                                     BETWEEN

                   CR STRATEGIES, L.L.C. AND NEORX CORPORATION

                                FEBRUARY 28, 2001

<PAGE>   2

1.    OVERVIEW. This agreement states the terms and conditions by which CR
      Strategies, L.L.C. will deliver and NeoRx Corporation will receive any or
      all of the services provided by CR Strategies, L.L.C. The specific
      services to be provided hereunder are identified and described in detail
      in the applicable SERVICE LEVEL AGREEMENT attached to this Agreement. Each
      SERVICE LEVEL AGREEMENT accepted and executed by both parties is hereby
      incorporated by reference into this agreement. This agreement is intended
      to cover any and all services ordered by NeoRx Corporation and provided by
      CR Strategies, L.L.C.

2.    DEFINITIONS. When used in this Agreement, the "BOLDED" terms listed below
      shall have the following meanings:

(a)   "NEORX CORPORATION TECHNOLOGY" shall mean any proprietary technology owned
      by NeoRx Corporation, or licensed to NeoRx Corporation by third parties,
      and all similar proprietary information provided to CR Strategies, L.L.C.
      by NeoRx Corporation in connection with CR Strategies, L.L.C.'s provision
      of services to NeoRx Corporation.

(b)   "CONFIDENTIAL INFORMATION" shall mean any information disclosed by either
      party to the other party, directly or indirectly, in writing, orally or by
      inspection of tangible objects that is designated as "Confidential",
      "Proprietary" or some other similar designation, including information
      disclosed to a disclosing party by third parties. Confidential Information
      shall not include any information that: is or becomes publicly known and
      generally available without violation of this Agreement; is in the
      possession of the receiving party prior to the disclosure without the
      obligation to maintain its confidentiality; is independently developed by
      the receiving party without use of or reference to the disclosing party's
      Confidential Information; is obtained from third parties without
      restrictions on disclosure; or is required by law or legal process to be
      disclosed by the receiving party, provided that, if permitted, the
      receiving party gives the disclosing party prompt written notice prior to
      such disclosure.

(c)   "CR STRATEGIES, L.L.C. TECHNOLOGY" shall mean any designs, concepts,
      reports, documentation, written materials, and any techniques, methods,
      patterns, formulas and any and all intellectual property rights used,
      invented, developed or delivered by CR Strategies, L.L.C. in the course of
      providing services.

(d)   "EFFECTIVE DATE" shall mean the date on which authorized representatives
      of NeoRx Corporation and CR Strategies, L.L.C have executed this Master
      Service Agreement.

<PAGE>   3

3.    SERVICE LEVEL AGREEMENT. A SERVICE LEVEL AGREEMENT is attached to this
      Master Service Agreement. Extensions or modifications to such SERVICE
      LEVEL AGREEMENT may be requested by NeoRx Corporation subject to any
      procedures set forth in such SERVICE LEVEL AGREEMENT or herein, and shall
      be subject to CR Strategies, L.L.C.'s approval and execution of an
      amendment to the SERVICE LEVEL AGREEMENT or, if appropriate, a new SERVICE
      LEVEL AGREEMENT.

4.    PAYMENTS. NeoRx Corporation agrees to pay to CR Strategies, L.L.C.
      according to the schedule provided in the attached SERVICE LEVEL
      AGREEMENT.

      NeoRx Corporation shall remit payment to CR Strategies, L.L.C.,
      referencing the CR Strategies, L.L.C. invoice number, to:

               CR Strategies, L.L.C.
               21 Kimberly Court
               Collinsville, IL 62234

               Attn:  Accounts Receivable

      or to such other address as CR Strategies, L.L.C. shall designate in
      writing to NeoRx Corporation.

5.    OWNERSHIP AND LICENSE. The documentation, enhancements, revisions,
      updates, upgrades, modifications, and derivative works thereto, and all
      other items delivered by CR Strategies, L.L.C. under this Agreement are
      owned by NeoRx Corporation.

6.    CONFIDENTIAL INFORMATION. Each party agrees not to use any Confidential
      Information of the other party for any purpose except in the performance
      of the services. Each party agrees not to disclose any Confidential
      Information of the other party to such party's employees or to third
      parties, except those who need to know such information for the purposes
      hereof. Each party agrees that it shall take reasonable efforts to protect
      the secrecy of and avoid disclosure and unauthorized use of any
      Confidential Information of the other party. Without limiting the
      foregoing, each party shall take at least those measures that it takes to
      protect its most highly confidential information. All documents and other
      tangible objects containing or representing Confidential Information which
      have been disclosed by either party to the other party, and all copies
      thereof which are in the possession of the receiving party, shall be and
      remain the property of the disclosing party and shall promptly be returned

<PAGE>   4

      to the disclosing party upon the request of the disclosing party. Except
      as expressly provided herein, nothing contained in this Agreement is
      intended to grant any rights to either party under any patent, mask work
      right, copyright, trademark, service mark or other intellectual property
      right of the other party.

7.    LIMITED WARRANTY; LIMITATION OF LIABILITY.

      (a)   CR Strategies, L.L.C. warrants that the services shall materially
            comply with the specifications for such services set forth in the
            attached SERVICE LEVEL AGREEMENT. To the extent that any failure of
            the services to comply with the specifications results in a failure
            or inability of CR Strategies, L.L.C. to provide services to NeoRx
            Corporation, CR Strategies, L.L.C.'s obligations and liability with
            respect to such failure, and NeoRx Corporation's sole remedy with
            respect to such failure, will be limited to a refund of that portion
            of the SERVICE LEVEL AGREEMENT total cost that is attributable to
            the specific services giving rise to the claim for damages.

            Subject to the limitations set forth herein, NeoRx Corporation
            agrees to defend, indemnify and hold CR Strategies, L.L.C., and its
            officers, employees and agents harmless against and for all losses,
            causes of action, liability, costs, expenses, claims and damages,
            including all expenses of litigation, reasonable attorney's fees and
            court costs, that either party may at any time suffer or sustain or
            become liable for, due to injury or death of a person, or for damage
            to any property arising out of, in connection with, or incidental to
            the service(s) provided by CR Strategies, L.L.C. under the terms of
            this agreement.

      (b)   Except for NeoRx Corporation's payment obligations in section 4
            neither party shall be liable for any special, indirect, incidental
            or consequential damages (even if advised of the possibility of such
            damage), including without limitation, lost profits or lost savings,
            loss of use of services (except as specifically provided in the
            attached SERVICE LEVEL AGREEMENT), cost of capital, cost of
            substitute services or re-procurement, downtime costs, or damages
            resulting from loss of use of data or from third party claims. CR
            Strategies, L.L.C. shall have no liability from damages resulting
            from NeoRx Corporation's failure to perform their responsibilities
            hereunder, including, but not limited to, NeoRx Corporation's
            failure to provide accurate and complete information to CR
            Strategies, L.L.C. In no event, shall CR Strategies, L.L.C.'s
            liability for damages hereunder exceed the amounts paid to CR
            Strategies, L.L.C. by NeoRx Corporation for the services giving

<PAGE>   5

            rise to the claim for damages. NeoRx Corporation recognizes that the
            fees specified in the attached SERVICE LEVEL

      (c)   AGREEMENT are based in part on the limited warranty and limitation
            of liability set forth above. The remedies specified in this
            agreement are exclusive.

8.    WORKMANSHIP. CR Strategies, L.L.C. represents and warrants that all of the
      services specified in the attached SERVICE LEVEL AGREEMENT will be
      performed in a good, workmanlike and professional manner in accordance
      with industry standards by qualified persons fully familiar with the
      requirements for such services.

9.    FORCE MAJEURE. Except with respect to payment obligations, neither party
      shall be liable, nor shall any credit allowance or other remedy be
      extended, for any failure to fulfill its obligations under this Agreement
      due to causes beyond such party's reasonable control, including, but not
      limited to: acts of God, flood, extreme weather, fire or other natural
      calamity; any law, order, regulation, direction, action, or request of any
      governmental entity or any civil or military authority; unavailability of
      rights-of-way or materials; national emergencies, insurrections, riots, or
      wars; or strikes, lock-outs, work stoppages, or other labor difficulties.
      Each party agrees to notify the other party, as soon as possible, if such
      an event has occurred. The time for completion of any obligation to which
      this provision applies shall be extended for a period equivalent to the
      delay except for payment obligations, which shall be extended by a maximum
      of 10 days.

10.   INITIAL DISPUTE RESOLUTION. Except in the case of a dispute in which a
      party seeks injunctive relief or must file suit in order to avoid
      expiration of the applicable statute of limitations, all disputes shall be
      referred to the senior executives of the parties for resolution. If the
      dispute is not resolved within 60 days of receipt of the initiating
      party's written notice, or if the senior executives fail to discuss the
      dispute(s) within 30 days of receipt of the initiating party's notice,
      either party may pursue any and all remedies available at law.

11.   ASSIGNMENT. Either party may transfer its rights and duties under this
      Agreement to an entity which has acquired all of such party's capital
      stock or all or substantially all of such party's assets, provided that:
      (i) the acquiring entity is not a competitor of the other party, (ii) the
      acquiring entity agrees in writing to be bound by the terms of this
      Agreement, (iii) the acquiring entity is capable of meeting all of its
      obligations under this Agreement, (iv) the other party is in full
      compliance with its obligations under this Agreement, and (v) the other
      party consents in writing to such transfer in advance, which consent shall
      not be unreasonably withheld. In all other cases, neither this Agreement
      nor any rights or licenses granted

<PAGE>   6

      hereunder may be assigned, or duties delegated whether by operation of law
      or otherwise, by either party without the prior written consent of the
      other party. Any attempted assignment or delegation in violation of this
      Section shall be void and ineffective for all purposes. This Agreement
      shall be binding upon and inure to the benefit of NeoRx Corporation and
      any permitted assignee or successor of either party.

12.   TERM AND TERMINATION. This Agreement shall become effective on the
      Effective Date and shall remain in effect for the period specified in the
      attached SERVICE LEVEL AGREEMENT.

(a)   TERMINATION FOR MATERIAL BREACH.

(i)   In the event of any other material breach of this Agreement, the
      non-breaching party shall give the breaching party written notice
      describing such breach. In the event that the breaching party fails to
      cure such material breach within 30 days after receipt of written notice
      of such breach from the non-breaching party, the non-breaching party shall
      be entitled to terminate this Agreement upon written notice to the
      breaching party.

(ii)  Upon any termination of this Agreement for material breach by CR
      Strategies, L.L.C., NeoRx Corporation shall be entitled to a pro rata
      refund of amounts paid in advance for services.

(b)   INSOLVENCY. In the event either party shall (i) be declared bankrupt,
      become subject to any proceedings relating to its liquidation,
      reorganization, or insolvency, whether voluntary or involuntary, or for
      the appointment of a trustee or receiver or similar official, of or for it
      or any part of its property, or (ii) fail generally, or admit in writing
      its inability to pay its debts as they become due, or (iii) make a general
      assignment for the benefit of creditors, or (iv) be dissolved or otherwise
      cease business as an ongoing business entity, then the other party may,
      upon thirty (30) days prior written notice, terminate this Agreement for
      cause. In the event of the commencement of a case under the Bankruptcy
      Code by or against either party, and during the period prior to the entry
      of an order directing or authorizing the other party or its trustee in
      bankruptcy to assume, reject or otherwise terminate this Agreement, such
      party may exercise its rights under Bankruptcy Code Section 365(n), as
      such section may be amended or supplemented from time to time, and the
      exercise of such rights or resort to any remedies provided thereunder
      shall not be deemed the exclusive rights and/or remedies available to such
      party, but such party is entitled to obtain any relief to the fullest
      extent provided by applicable bankruptcy or nonbankruptcy law.

<PAGE>   7

(c)   RENEWAL AND EXPIRATION.

(i)   Apart from the above conditions the parties shall have the right to renew
      this Agreement upon mutual agreement, and it shall continue in effect for
      so long as there is a SERVICE LEVEL AGREEMENT in effect. Unless
      specifically provided otherwise, the term of a SERVICE LEVEL AGREEMENT,
      and NeoRx Corporation's right to use the services specified in such
      SERVICE LEVEL AGREEMENT, shall begin on the commencement date specified in
      Section 12 and continue in effect for the term stated in the SERVICE LEVEL
      AGREEMENT. Thereafter, the parties shall have the right to renew, upon
      mutual agreement, a SERVICE LEVEL AGREEMENT for successive renewal terms
      of duration equal to the original agreement.

(ii)  In the event of any expiration or termination of this Agreement NeoRx
      Corporation shall pay CR Strategies, L.L.C. on or before the effective
      date of termination all fees due, including but not limited to any out-of
      pocket expenses and reasonable travel and related expenses incurred up to
      the date of termination. Notwithstanding any termination or expiration of
      this Agreement, Sections 2, 4, 5, 6, 7, 8, 9, 10, 11, 12(c)(ii), 16, and
      17 shall survive termination.

13.   GOVERNING LAW. Interpretation, construction and enforcement of this
      Agreement shall be pursuant to the laws of Washington, U.S.A. The parties
      agree that the United Nations Convention for the International Sale of
      Goods shall not apply to this Agreement. Both parties agree to submit to
      the exclusive jurisdiction and venue of and agree that any cause of action
      arising under this Agreement shall be brought in a court in Washington.

14.   NOTICES. All notices required to be given under this Agreement shall be in
      writing and shall be deemed effective when received and shall be delivered
      in person, by facsimile, with a confirmation copy sent as provided herein,
      or by mail, postage prepaid, for delivery as registered or certified mail
      addressed, return receipt requested. All notices shall be deemed received
      (i) if given by hand, immediately, (ii) if given by registered mail, 3
      business days after posting, (iii) if given by express courier service,
      the next business day, or (iv) if given by facsimile, upon receipt thereof
      by the recipient's facsimile machine as indicated either in the sender's
      identification line produced by the recipient's facsimile machine or in
      the sender's transmission confirmation report as produced electronically
      by the sender's facsimile machine. Notices to CR Strategies, L.L.C. shall
      be sent to:

<PAGE>   8

            CR Strategies, L.L.C.
            605 Alder Street
            Prescott, AZ 86301

            Attn:  Raymond F. Schmelter, PhD, MBA

            FAX Number (520) 445-1378

      or, in the case of NeoRx Corporation, to:

            NeoRx Corporation
            410 West Harrison Street
            Seattle, WA 98119-4007

            Attn: Paul G. Abrams, M.D., J.D.

      or to such other address as either party may designate in writing to the
      other from time to time.

15.   ENTIRE AGREEMENT. This Agreement and the SERVICE LEVEL AGREEMENT
      referenced herein constitute the full and final expression of agreement
      between the parties with respect to the subject matter hereof and
      supersede all previous agreements and understandings, whether written or
      oral, relating to the subject matter hereof. This Agreement may not be
      altered, amended or modified except by written instrument signed by the
      duly authorized representatives of both parties. Any different, additional
      and/or pre-printed terms contained on purchase orders or other terms and
      conditions submitted by NeoRx Corporation shall be void. As used herein,
      "include" and its derivatives shall be deemed to mean, "including but not
      limited to".

16.   SEVERABILITY. Should any term of this Agreement, for any reason, be held
      to be illegal or unenforceable by a court of competent jurisdiction, the
      remaining terms of this Agreement will continue in full force and effect,
      and the offending term shall be limited or modified to the extent
      necessary to make it enforceable.

17.   GENERAL. (a) Either party may disclose that NeoRx Corporation has retained
      CR Strategies, L.L.C.'s services, and CR Strategies, L.L.C. may describe
      in general, non-confidential terms, CR Strategies, L.L.C.'s work under the
      Agreement in its marketing materials. Any other disclosure as to the
      nature of this Agreement or the work being performed hereunder shall be
      subject to the prior approval of both parties. (b) No waiver of or

<PAGE>   9

      failure to act regarding any breach of this Agreement shall constitute a
      waiver of any other breach. (c) Subject to applicable law, no action,
      other than an action for nonpayment, arising out of or relating to this
      Agreement may be brought by either party more than 2 years after the cause
      of action has accrued, provided that neither party shall be precluded from
      making a counterclaim or cross-claim in an action commenced by the other
      party or by a third party. CR Strategies, L.L.C.'s contractors may be
      direct and intended third party beneficiaries of this Agreement and may be
      entitled to enforce this Agreement directly against NeoRx Corporation to
      the extent that (i) this Agreement relates to the acquisition of CR
      Strategies, L.L.C. contractor's services, and (ii) CR Strategies, L.L.C.
      fails to enforce the terms of this Agreement on CR Strategies, L.L.C.
      contractors' behalf. This Agreement may be amended or modified only by a
      written instrument signed by an authorized representative of CR
      Strategies, L.L.C. and NeoRx Corporation.

      By the signatures of their duly authorized representatives below, CR
      Strategies, L.L.C. and NeoRx Corporation, intending to be legally bound,
      agree to all of the provisions of this Agreement.

ACCEPTED & AGREED TO:

CR Strategies, L.L.C.                     NeoRx Corporation

By:                                       By:

Adeoye Y. Olukotun, MD, MPH

Title: CEO                                Title:

Date: February 28, 2001                   Date:

By:

Raymond F. Schmelter, PhD, MBA

Title: President and COO

Date: February 28, 2001

<PAGE>   10

                      ATTACHMENT A. SERVICE LEVEL AGREEMENT

                                     BETWEEN

                   CR STRATEGIES, L.L.C. AND NEORX CORPORATION

                                FEBRUARY 28, 2001

                                    OVERVIEW

CR Strategies, L.L.C. will function as the Senior Management of Medical and
Regulatory Affairs for NeoRx Corporation through the end of December 2001 and
will perform the specific tasks listed under Section B below.

NeoRx Corporation and CR Strategies, L.L.C. have agreed that CR Strategies,
L.L.C. will endeavor to achieve the following objectives for this engagement:

-  Identify, propose, and build systems, processes and human resources
   internally at NeoRx Corporation toward establishing an NDA-ready
   organization.

-  Manage, through direct reporting and supervision, all Medical & Regulatory
   Affairs personnel. Mentor the STR program and its personnel through the term
   of the engagement.

            One of CR Strategies, L.L.C.'s principal members will be [*] for the
            duration of the engagement.

            CR Strategies, L.L.C. will report to Dr. Doug Given for the duration
            of the engagement.

[*] DESIGNATES PORTIONS OF THIS DOCUMENT THAT HAVE BEEN OMITTED PURSUANT TO A
REQUEST FOR CONFIDENTIAL TREATMENT FILED SEPARATELY WITH THE COMMISSION.

Services provided by CR Strategies, L.L.C. will commence on the date on which
NeoRx Corporation signs the Master Service Agreement to which this SERVICE LEVEL
AGREEMENT is attached and will terminate not later than December 31, 2001.

                                  WORK PRODUCT

CR Strategies, L.L.C. will perform the following specific tasks for NeoRx
Corporation:

-  Identify and procure, according to the terms in Section D below, a complete
   problem-solving team to manage the STR clinical and regulatory program.

<PAGE>   11

-  Form [*] capable of crossing the threshold acceptable to FDA. All consulting
   costs for these experts will be billed by the consultants directly to NeoRx
   Corporation.

-  Prepare for [*] with FDA.

-  Develop [*] acceptable to FDA.

-  Identify and set up clinical sites appropriate to performing [*].

-  Manage the performance of the [*] clinical study.

-  Analyze, submit to FDA, and defend clinical data developed in [*].

-  Develop a protocol for performing [*] for a subsequent [*] clinical trial.

-  Initiate the [*] clinical trial.

-  Manage the relationship with PPD Contract Research Organization.

-  Perform potential problem analysis and develop a plan to manage regulatory
   risk.

-  Develop internal NeoRx systems to prepare for NDA submission.

-  Assist in identifying, recruiting, and training NeoRx human resources to
   complete the [*] clinical trial and submit the NDA.

NeoRx Corporation will provide CR Strategies, L.L.C. with full access to its STR
project employees, subcontractors, and consultants, and all necessary STR
project data and documentation to allow CR Strategies, L.L.C. to fulfill its
obligations under this SERVICE LEVEL AGREEMENT.

             MATERIALS, SHIPPING, TRAVEL, SITE VISITS, PHOTOCOPYING

Expenses incurred by CR Strategies, L.L.C. in providing these services are
anticipated to not exceed approximately 20% of the price of this SERVICE LEVEL
AGREEMENT and will be separately billed to NeoRx Corporation on a bi-weekly
basis. If for any reason prices exceed 20% of the price of this SERVICE LEVEL
AGREEMENT, CR Strategies, L.L.C. will obtain NeoRX Corporation's approval prior
to proceeding. Expected costs include, but are not limited to, travel, travel
expenses (meals and lodging), telephone, fax, courier, shipping costs, copying,
materials, etc. When either party to this agreement deems travel necessary, CR
Strategies, L.L.C. will contact NeoRx Corporation to reach agreement about costs
and trip duration.

                          PRICING AND PAYMENT SCHEDULE

CR Strategies, L.L.C. will perform the tasks indicated in Section B for [*],
plus [*] stock options ([*] for each CR Strategies, L.L.C. principal member),
plus expenses as described in Section C. The cost breakdown for the engagement
is as follows:

<TABLE>
<CAPTION>
<S>                                 <C>
CR Strategies Salaries              [*]
Administrative Overhead (25%)       [*]
            Total                   [*]
</TABLE>

One hundred percent of Administrative Overhead [*] will be invoiced immediately
upon commencement of the engagement. [*] of the CR Strategies, L.L.C. salaries
shown above ([*]) will be invoiced at the end of each calendar quarter,
commencing March 30, 2001. In addition, it is anticipated that the following
professionals will subcontract directly with NeoRx, but be managed by CR
Strategies, L.L.C., for approximately the following salaries in order to further
the objectives listed in Section A:

<PAGE>   12

<TABLE>
<CAPTION>
      --------------------------------------------------------------------------
                                       Fully-
      Position                         Loaded
                                     Annualized  Hours/  Hourly  Weeks/ 10-Month
                                       Salary     Week    Rate    Year   Total
      --------------------------------------------------------------------------
<S>                                  <C>         <C>     <C>     <C>     <C>
      Ph.D. Regulatory Director           [*]     [*]     [*]     [*]     [*]
      MD Safety Reviewer                  [*]     [*]     [*]     [*]     [*]
      M.S. Statistician                   [*]     [*]     [*]     [*]     [*]
      M.S. Senior CRA                     [*]     [*]     [*]     [*]     [*]
      B.S. Senior CRA Safety Reviewer     [*]     [*]     [*]     [*]     [*]
      B.S. Regulatory Specialist          [*]     [*]     [*]     [*]     [*]
      B.S. Medical Writer                 [*]     [*]     [*]     [*]     [*]
      --------------------------------------------------------------------------
                                                         Total            [*]
      --------------------------------------------------------------------------
</TABLE>

CR Strategies, L.L.C. will invoice NeoRx Corporation a one-time charge of 10% of
the 10-month salary for each of these, or other similar, professionals that CR
Strategies, L.L.C. successfully recruits as subcontractors to the STR project.

The price in this quotation is valid for 30 days from the date on the cover
sheet of this SERVICE LEVEL AGREEMENT.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00025-of-00352.parquet"}]]